Bronchospasm News and Research

RSS
Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Phase III clinical trial data of Cayston versus TIS in CF patients with P. aeruginosa presented at ECFC 2010

Phase III clinical trial data of Cayston versus TIS in CF patients with P. aeruginosa presented at ECFC 2010

Beta-blocker medications provide new hope for patients with COPD: Study

Beta-blocker medications provide new hope for patients with COPD: Study

Data from Phase 3 clinical trials of PROVENGE in advanced prostate cancer to be presented at ASCO 2010

Data from Phase 3 clinical trials of PROVENGE in advanced prostate cancer to be presented at ASCO 2010

Study: EIB may affect lives and health of public if not addressed properly

Study: EIB may affect lives and health of public if not addressed properly

FDA's warning over LABA medications for asthma: AANMA offers guidance

FDA's warning over LABA medications for asthma: AANMA offers guidance

FDA issues approval for Gileads's Cayston for respiratory symptoms in cystic fibrosis

FDA issues approval for Gileads's Cayston for respiratory symptoms in cystic fibrosis

Survey reveals need for better access to levalbuterol for asthma patients

Survey reveals need for better access to levalbuterol for asthma patients

Sepracor to be acquired by Dainippon Sumitomo Pharma for $2.6 billion

Sepracor to be acquired by Dainippon Sumitomo Pharma for $2.6 billion

Mylan's subsidiary launches levalbuterol inhalation solution used for treating bronchospasm

Mylan's subsidiary launches levalbuterol inhalation solution used for treating bronchospasm

FDA approves Extavia for multiple sclerosis

FDA approves Extavia for multiple sclerosis

Athletes with asthma need more help from their team trainers

Athletes with asthma need more help from their team trainers

GlaxoSmithKline ready to supply Biota's Relenza to meet CDC recommendations

GlaxoSmithKline ready to supply Biota's Relenza to meet CDC recommendations

AstraZeneca responds to FDA advisory committees' recommendation on SYMBICORT

AstraZeneca responds to FDA advisory committees' recommendation on SYMBICORT

Popular COPD treatment increases risk for cardiac events, cardiac death

Popular COPD treatment increases risk for cardiac events, cardiac death

CFC-propelled inhalers no longer available as of Dec. 31 2008

CFC-propelled inhalers no longer available as of Dec. 31 2008

AstraZeneca submits sNDA for SYMBICORT in chronic obstructive pulmonary disease

AstraZeneca submits sNDA for SYMBICORT in chronic obstructive pulmonary disease

Naglazyme approved in Japan

Naglazyme approved in Japan

FDA approves only once-daily inhaled corticosteroid for children

FDA approves only once-daily inhaled corticosteroid for children

Watson receives FDA approval for generic DuoNeb

Watson receives FDA approval for generic DuoNeb